Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAN103 in Treatment-naive Gaucher Disease Type 1 and 3 (China, Phase I/II)
CTR20220507Phase 2Completed
- Sponsor
- CANbridge Pharmaceuticals Inc.
- Start
- Mar 2022
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of velaglucerase beta in Gaucher disease type 1 (GD1), Gaucher disease type 3, sponsored by CANbridge Pharmaceuticals Inc.. Started Mar 2022; status: completed.
02
Drugs
velaglucerase beta
03
Conditions
Gaucher disease type 1 (GD1)Gaucher disease type 3
Beyond the preview
Go deeper on CTR20220507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220507.